| Alkermes' Q1 Earnings and Revenues Fall Short of Estimates |
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations. |
zacks.com |
2025-05-02 16:10:32 |
Czytaj oryginał (ang.) |
| Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible |
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight gain with LYBALVI, addressing a major concern with mental health medications and supporting its market potential. |
seekingalpha.com |
2025-05-01 20:31:18 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings |
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 16:00:42 |
Czytaj oryginał (ang.) |
| Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript |
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Uy Ear - Mizuho Securities Joel Beatty - Baird David Hoang - Deutsche Bank Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to Alkermes' First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-01 15:21:05 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates |
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago. |
zacks.com |
2025-05-01 13:26:09 |
Czytaj oryginał (ang.) |
| Alkermes plc Reports First Quarter 2025 Financial Results |
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. |
prnewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) |
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may positively impact people living with AUD. |
prnewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline |
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:05:45 |
Czytaj oryginał (ang.) |
| Alkermes to Report First Quarter Financial Results on May 1, 2025 |
DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. |
prnewswire.com |
2025-04-17 20:00:00 |
Czytaj oryginał (ang.) |
| Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference |
DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. |
prnewswire.com |
2025-04-02 20:00:00 |
Czytaj oryginał (ang.) |
| Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 |
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia. |
zacks.com |
2025-04-02 14:35:47 |
Czytaj oryginał (ang.) |
| Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia |
DUBLIN , April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness. |
prnewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder |
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life – – 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect – DUBLIN , March 27, 2025 /PRNewswire/ -- People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations. |
prnewswire.com |
2025-03-27 09:00:00 |
Czytaj oryginał (ang.) |
| Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? |
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe. |
zacks.com |
2025-03-25 15:46:09 |
Czytaj oryginał (ang.) |
| GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait |
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily. |
investors.com |
2025-03-22 10:00:19 |
Czytaj oryginał (ang.) |
| Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? |
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-14 14:36:21 |
Czytaj oryginał (ang.) |
| Alkermes to Participate in Upcoming Investor Conferences |
DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. |
prnewswire.com |
2025-02-26 18:00:00 |
Czytaj oryginał (ang.) |
| Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment |
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment |
seekingalpha.com |
2025-02-25 07:08:12 |
Czytaj oryginał (ang.) |
| Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up |
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. |
zacks.com |
2025-02-13 14:01:17 |
Czytaj oryginał (ang.) |
| Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript |
Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Blair Jackson - Executive Vice President and Chief Operating Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI Jessica Fye - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Uy Ear - Mizuho Securities Troy Langford - TD Cowen Douglas Tsao - H.C. Wainwright Joel Beatty - Baird Operator Greetings, and welcome to the Alkermes Fourth Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-12 16:40:05 |
Czytaj oryginał (ang.) |
| Alkermes Plc EPS Soars Past Forecasts |
Alkermes (ALKS 2.50%), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76. |
fool.com |
2025-02-12 12:37:25 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-12 12:36:50 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates |
Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago. |
zacks.com |
2025-02-12 11:40:21 |
Czytaj oryginał (ang.) |
| Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 |
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN , Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company. |
prnewswire.com |
2025-02-12 09:00:00 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings |
Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-10 12:20:23 |
Czytaj oryginał (ang.) |
| Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 |
DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. |
prnewswire.com |
2025-02-05 18:00:00 |
Czytaj oryginał (ang.) |
| Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
DUBLIN , Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. |
prnewswire.com |
2025-01-02 18:00:00 |
Czytaj oryginał (ang.) |
| Alkermes to Participate in Upcoming Investor Conferences |
DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. |
prnewswire.com |
2024-11-25 18:00:00 |
Czytaj oryginał (ang.) |
| Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth |
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations. |
seekingalpha.com |
2024-11-24 11:58:43 |
Czytaj oryginał (ang.) |
| Alkermes to Participate in Two Upcoming Investor Conferences |
DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. |
prnewswire.com |
2024-11-11 18:00:00 |
Czytaj oryginał (ang.) |
| Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences |
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the 2024 Neuroscience Education Institute (NEI) Congress, taking place Nov. 7-10, 2024 in Colorado Springs, Colorado—represent important opportunities for Alkermes to showcase the breadth and depth of its work in neuroscience. |
prnewswire.com |
2024-11-07 09:00:00 |
Czytaj oryginał (ang.) |
| Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down |
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. |
zacks.com |
2024-10-25 15:11:14 |
Czytaj oryginał (ang.) |
| Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript |
Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fye - JPMorgan Jason Gerberry - Bank of America Marc Goodman - Leerink Partners Ash Fermot - UBS Douglas Tsao - H.C. |
seekingalpha.com |
2024-10-24 17:04:03 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say |
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-10-24 16:06:27 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates |
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. |
zacks.com |
2024-10-24 13:11:12 |
Czytaj oryginał (ang.) |
| Alkermes plc Reports Third Quarter 2024 Financial Results |
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year. |
prnewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. |
zacks.com |
2024-10-22 14:21:00 |
Czytaj oryginał (ang.) |
| Alkermes to Report Third Quarter Financial Results on October 24, 2024 |
DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. |
prnewswire.com |
2024-10-17 20:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Alkermes (ALKS) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-10-11 14:56:43 |
Czytaj oryginał (ang.) |
| Here's Why Alkermes (ALKS) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-10-10 14:50:24 |
Czytaj oryginał (ang.) |
| Alkermes to Host Investor Event to Review Orexin Portfolio Strategy |
DUBLIN , Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. |
prnewswire.com |
2024-09-25 12:00:00 |
Czytaj oryginał (ang.) |
| Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-09-23 14:51:25 |
Czytaj oryginał (ang.) |
| Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 |
̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster Presentation ̶ DUBLIN , Sept. 23, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the European Sleep Research Society's (ESRS) 27th Congress, Sleep Europe 2024, taking place Sept. |
prnewswire.com |
2024-09-23 11:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Alkermes (ALKS) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-09-20 14:41:31 |
Czytaj oryginał (ang.) |
| Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program |
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Application Period to Run From Sept. 20, 2024 Through Nov. 30, 2024 — DUBLIN , Sept. |
prnewswire.com |
2024-09-13 11:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Alkermes (ALKS) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-09-05 14:45:27 |
Czytaj oryginał (ang.) |